American Society of Human Genetics (ASHG) Annual Meeting October 15-19, 2019
A team from PaLM Molecular Diagnostics attended the American Society of Human Genetics (ASHG) Annual Meeting showcasing EpiSign - our world first clinical whole genome methylation test for diagnosing over 20 neurodevelopmental disorders. Current standard of care leaves over 50% of patients undiagnosed and many with genetic variants of unknown significance (VUS). EpiSign has the potential to consolidate a range of targeted assays and resolve all VUSs for a long list of critical genes.
Launched in 2018, EpiSign has gathered international attention as a breakthrough innovation in clinical epigenetics. Clinical distribution partners have now been established with Greenwood Genetics Centre in South Carolina for the US market and Amsterdam University Medical Centre for the European market. Reception at ASHG 2019 was excellent with interest from across the US, Brazil, Europe, Australia/NZ and more.
Congratulations to the whole team, Erfan Aref Eshghi, Jennifer Kerkhof, Alan Stuart, Jennefer Masters, Bekim Sadikovic, and Mike Kadour!
